Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | CASP1 | P29466 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MYC | P01106 | 1/20 | 0.45 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 5/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.43 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.37 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1194373 | 0.83 | TSHR (0.37) | TSHRCASP1SMN1; SMN2ALDH1A1MYC | |
| SCHEMBL1194394 | 0.79 | ALDH1A1 (0.42) | TSHRCASP1SMN1; SMN2ALDH1A1CA1 | |
| SCHEMBL22628276 | 0.78 | AKR1C2 (0.44) | TSHRALDH1A1AKR1C3AKR1C2PTGS2 | |
| SCHEMBL1194182 | 0.77 | ALDH1A1 (0.53) | ALDH1A1AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL29377565 | 0.77 | ALDH1A1 (0.53) | ALDH1A1AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL1633725 | 0.77 | RXRB (0.46) | ALDH1A1MYCAKR1C3AKR1C2PTGS2 | |
| SCHEMBL12392023 | 0.75 | KDM4E (0.41) | SMN1; SMN2ALDH1A1CYP1A2KDM4EMAPT | |
| SCHEMBL26979278 | 0.74 | AKR1C2 (0.44) | AKR1C3AKR1C2PTGS2PTGS1TAS2R14 | |
| SCHEMBL195310 | 0.74 | TSHR (0.63) | TSHRCASP1SMN1; SMN2ALDH1A1MYC | |
| SCHEMBL23141189 | 0.73 | PTGS2 (0.43) | TSHRAKR1C3AKR1C2PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404893-B2 | Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-03-26 | — | — | US | disclosed |
| US-20110306670-A1 | PENTAFLUOROSULFANYLBENZOYLGUANIDINES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS OR DIAGNOSTIC AIDS, AND MEDICAMENTS COMPRISING THEM | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-12-15 | — | — | US | disclosed |
| US-8008352-B2 | N-[2-Chloro-4-pentafluorosulfanylbenzoyl]guanidine; ischemia, reperfusion, arrythmia angina pectoris; inhibit the cellular sodium-proton antiporter (Na+/H+ exchanger, NHE); stability, longer half-life in vivo, high bioavailability | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-08-30 | — | — | US | disclosed |
| US-20080200553-A1 | PENTAFLUOROSULFANYLBENZOYLGUANIDINES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS OR DIAGNOSTIC AIDS, AND MEDICAMENTS COMPRISING THEM | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-08-21 | — | — | US | disclosed |
| US-7375138-B2 | Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-05-20 | — | — | US | disclosed |
| US-20030216476-A1 | Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them | AVENTIS PHARMA DEUTSHCHLAND GMBH (DE) | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200553-A1 | PENTAFLUOROSULFANYLBENZOYLGUANIDINES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS OR DIAGNOSTIC AIDS, AND MEDICAMENTS COMPRISING THEM | TNNI3, TNNT2, SDHB | TSHR 2387/4885CASP1 1205/4885SMN1; SMN2 2738/4885 |
| US-20110306670-A1 | PENTAFLUOROSULFANYLBENZOYLGUANIDINES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS OR DIAGNOSTIC AIDS, AND MEDICAMENTS COMPRISING THEM | TNNI3, TNNT2, SDHB | TSHR 2387/4885CASP1 1205/4885SMN1; SMN2 2738/4885 |
| US-20030216476-A1 | Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them | TNNI3, TNNT2, SDHB | TSHR 2514/4885CASP1 989/4885SMN1; SMN2 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.